Glow Lifetech Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Glow Lifetech has been growing earnings at an average annual rate of 16.4%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 155.3% per year.
Información clave
16.4%
Tasa de crecimiento de los beneficios
32.3%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 7.3% |
| Tasa de crecimiento de los ingresos | 155.3% |
| Rentabilidad financiera | n/a |
| Margen neto | -412.7% |
| Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
No hay actualizaciones
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Glow Lifetech. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -1 | 1 | 0 |
| 31 Mar 24 | 0 | -2 | 1 | 0 |
| 31 Dec 23 | 0 | -2 | 1 | 0 |
| 30 Sep 23 | 0 | -2 | 1 | 0 |
| 30 Jun 23 | 0 | -2 | 1 | 0 |
| 31 Mar 23 | 0 | -2 | 1 | 0 |
| 31 Dec 22 | 0 | -2 | 1 | 0 |
| 30 Sep 22 | 0 | -1 | 1 | 0 |
| 30 Jun 22 | 0 | -1 | 1 | 0 |
| 31 Mar 22 | 0 | -2 | 2 | 0 |
| 31 Dec 21 | 0 | -11 | 5 | 0 |
| 30 Sep 21 | 0 | -12 | 5 | 0 |
| 30 Jun 21 | 0 | -13 | 5 | 0 |
| 31 Mar 21 | 0 | -12 | 4 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 30 Sep 20 | 0 | -2 | 1 | 0 |
| 30 Jun 20 | 0 | -1 | 1 | 0 |
| 31 Mar 20 | 0 | -1 | 1 | 0 |
Ingresos de calidad: 9DO is currently unprofitable.
Margen de beneficios creciente: 9DO is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 9DO is unprofitable, but has reduced losses over the past 5 years at a rate of 16.4% per year.
Acelerando crecimiento: Unable to compare 9DO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: 9DO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Rentabilidad financiera
Alta ROE: 9DO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.